RECORA- Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy
Phase of Trial: Phase IV
Latest Information Update: 05 Sep 2017
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms RECORA
- Sponsors Bayer
- 30 Aug 2017 Status changed from active, no longer recruiting to completed.
- 30 Jul 2017 Planned End Date changed from 30 Jun 2017 to 31 Aug 2017.
- 30 Jul 2017 Planned primary completion date changed from 30 Jun 2017 to 31 Aug 2017.